Cipla Ltd. — Regulatory Filings 2021

Nov 17, 2021

17th November 2021

• (1) BSE Limited Listing Department Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001
• (2) National Stock Exchange of India Ltd Listing Department Exchange Plaza, 5th floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Sub: Press Release - Cipla launches Spirofy®: Strengthens its lung leadership position by facilitating early diagnosis for COPD

Dear Sir / Madam,

Please find enclosed press release dated 17th November 2021 for the captioned subject.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking you,

Yours faithfully, For Cipla Limited RAJENDRA KUMAR Digitally signed by CHOPRA

RAJENDRA KUMAR Date: 2021.11.17 06:59:52

Rajendra Chopra Company Secretary CHOPRA +05'30'

Encl.as above

Prepared by: Juzer Masta

Cipla launches Spirofy®: Strengthens its lung leadership position by facilitating early diagnosis for COPD1

• Spirofy®: India's first pneumotach based portable wireless Spirometer for diagnosis of Chronic Obstructive Pulmonary Disorder (COPD) and asthma
• COPD is the 2nd most common cause of deaths in India2

Mumbai, India; November 17, 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") announced the launch of Spirofy®, India's first pneumotach based portable, wireless Spirometer, on World COPD Day. With this launch, the company intends to revolutionize Obstructive Airway Disease (OAD) diagnosis, in line with its ambition to strengthen its position as the lung leader in India. This a part of the Company's #LungAttack campaign that endeavors to drive awareness about COPD and encourage early diagnosis.

Cipla's Spirofy® is a result of 5 years of meticulous in-house research by the Integrated Product Development (IPD) team, and it aims to transform Obstructive Airway Disease (OAD) diagnosis in India. This advanced device ensures high result accuracy and individual patient safety using Bacterial Viral Filters. Spirofy® is entirely wireless with good battery backup, making it suitable for use in outdoor camps, remote areas with power shortages, or simply providing physicians' flexibility and ease of use. The device generates reports in real-time, which can be printed using a portable wireless thermal printer instantly, or a pdf version can be shared on the phone. Cipla will undertake training of physicians in the interpretation of spirometry results.

Spirometry is the gold standard for COPD diagnosis, however owing to the bulky size, complex functionality, need for regular maintenance are some reasons that impacted the widespread acceptance of conventional spirometers by medical practitioners. This resulted in underdiagnosis or misdiagnosis of COPD cases in India. Currently, COPD remains the 2nd most common cause of death² in India after heart diseases, where India alone bears 32% of the global COPD burden.

Commenting on the launch, Mr. Umang Vohra (MD and Global CEO, Cipla Limited) said, "Cipla has been steadfastly focused on addressing the world's growing respiratory disease burden, and with this launch, we see ourselves steadily advancing to combat chronic respiratory ailments like COPD. The Spirofy® launch aims to help doctors across the country to improve lives of patients through accurate and affordable diagnosis."

¹COPD – Chronic Obstructive Pulmonary Disorder

² Global burden of Diseases Report published in 2017

Over the last six decades, Cipla relentlessly worked to improve access to life-saving drugs across the care continuum and provided a wide range of drug-device combinations to improve the lung health of millions of people in India and other key emerging markets.

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA September 2021), 3rd largest in the pharma private market in South Africa (IQVIA MAT September 2021), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigmchanging offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

For queries, please contact

Corporate Communications

Heena Kanal

E-Mail: CorpComm@cipla.com